The development of a novel medicine for advanced prostate cancer
This project will deliver a novel treatment for prostate carcinoma, which is based on a unique and patented compound that is able to reverse Epithelial-Mesenchymal Transition (EMT). EMT is a process associated with cancer invasion, therapy resistance, and the plasticity of cancer- and metastasis-initiating cells. Since EMT is associated with many epithelial cancer types, this drug can be applied to different types of carcinomas including breast, lung, pancreas, skin and bladder cancer.
2 460 420.00€
Cytology, Cancerology, Oncology
Other therapeutic (including defibrillators)